Sotera Health will announce Q4 2025 financial results on February 24, 2026, followed by a conference call.
Quiver AI Summary
Sotera Health Company, a prominent provider of sterilization solutions and lab testing services for healthcare, announced that it will release its financial results for the fourth quarter and full year ending December 31, 2025, before the market opens on February 24, 2026. Following this release, management will host a conference call at 9:00 a.m. Eastern Time to discuss the company's performance and operating highlights, which will be accessible via a live webcast on its Investor Relations website. A replay of the call will also be made available later that day. Sotera Health operates through three business segments - Sterigenics, Nordion, and Nelson Labs - and is dedicated to its mission of safeguarding global health.
Potential Positives
- Sotera Health is set to announce its financial results for Q4 and full-year 2025, indicating transparency and accountability to investors.
- A scheduled conference call to discuss the financial results and operating highlights shows the company's commitment to engaging with stakeholders.
- The availability of a live webcast and a subsequent replay of the conference call enhances accessibility for investors and analysts.
- The mention of ongoing updates in the Investor Relations section suggests a proactive approach to communication with investors regarding relevant matters.
Potential Negatives
- None
FAQ
When will Sotera Health release its financial results?
Sotera Health will release its financial results for Q4 and full-year 2025 on February 24, 2026, before market opens.
What time is the conference call for financial results?
The conference call to discuss financial results will start at 9:00 a.m. Eastern Time on February 24, 2026.
How can I access the webcast of the conference call?
A live webcast of the conference call can be accessed via the Investor Relations section of Sotera Health's website.
Will a replay of the conference call be available?
Yes, a replay of the webcast will be accessible later on February 24, 2026.
Where can I find updates on developments related to Sotera Health?
Investors can find updates on recent developments in the Investor Relations section of the Sotera Health website.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SHC Insider Trading Activity
$SHC insiders have traded $SHC stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $SHC stock by insiders over the last 6 months:
- PINCUS & CO. WARBURG has made 0 purchases and 6 sales selling 79,440,000 shares for an estimated $1,243,555,200.
- INVESTMENT XI LLC GTCR has made 0 purchases and 3 sales selling 26,480,000 shares for an estimated $414,518,400.
- MICHAEL B. JR. PETRAS (Chairman & CEO) has made 0 purchases and 3 sales selling 750,000 shares for an estimated $12,337,499.
- MICHAEL P RUTZ (President of Sterigenics) sold 126,611 shares for an estimated $2,074,305
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SHC Revenue
$SHC had revenues of $311.3M in Q3 2025. This is an increase of 9.05% from the same period in the prior year.
You can track SHC financials on Quiver Quantitative's SHC stock page.
$SHC Hedge Fund Activity
We have seen 194 institutional investors add shares of $SHC stock to their portfolio, and 92 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WARBURG PINCUS LLC removed 12,000,000 shares (-16.3%) from their portfolio in Q3 2025, for an estimated $188,760,000
- GTCR LLC removed 8,000,000 shares (-16.3%) from their portfolio in Q3 2025, for an estimated $125,840,000
- SCULPTOR CAPITAL LP added 7,658,200 shares (+57.4%) to their portfolio in Q4 2025, for an estimated $135,090,648
- DARSANA CAPITAL PARTNERS LP added 4,990,000 shares (+24.9%) to their portfolio in Q3 2025, for an estimated $78,492,700
- SACHEM HEAD CAPITAL MANAGEMENT LP added 3,735,000 shares (+47.2%) to their portfolio in Q4 2025, for an estimated $65,885,400
- SESSA CAPITAL IM, L.P. added 3,619,022 shares (+57.4%) to their portfolio in Q3 2025, for an estimated $56,927,216
- VOSS CAPITAL, LP added 3,208,482 shares (+427.8%) to their portfolio in Q4 2025, for an estimated $56,597,622
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SHC Analyst Ratings
Wall Street analysts have issued reports on $SHC in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 01/09/2026
- William Blair issued a "Outperform" rating on 12/18/2025
- BMO Capital issued a "Outperform" rating on 11/13/2025
- Barclays issued a "Overweight" rating on 10/02/2025
To track analyst ratings and price targets for $SHC, check out Quiver Quantitative's $SHC forecast page.
$SHC Price Targets
Multiple analysts have issued price targets for $SHC recently. We have seen 5 analysts offer price targets for $SHC in the last 6 months, with a median target of $20.0.
Here are some recent targets:
- Jason Bednar from Piper Sandler set a target price of $24.0 on 01/09/2026
- Sean Dodge from RBC Capital set a target price of $24.0 on 01/09/2026
- Sean Dodge from BMO Capital set a target price of $19.0 on 11/13/2025
- Luke Sergott from Barclays set a target price of $20.0 on 11/05/2025
- Casey Woodring from JP Morgan set a target price of $16.0 on 11/05/2025
Full Release
CLEVELAND, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2025 before the market opens on Tuesday, February 24, 2026. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company’s operating highlights and financial results.
A live webcast of the conference call and accompanying materials can be accessed via the Investor Relations section of the Company’s website at Presentation & Events | Sotera Health . A replay of the webcast will be available later in the day on February 24.
Updates can be found from time to time on recent developments in matters relevant to investors on the Investor Relations section of the Company’s website at Investor Relations | Sotera Health . For developments related to Ethylene Oxide, updates can be found at Ethylene Oxide | Sotera Health .
About Sotera Health
Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics ® , Nordion ® and Nelson Labs ® . Sotera Health is committed to its mission, Safeguarding Global Health ® .
INVESTOR RELATIONS CONTACTS:
Jason Peterson
Vice President, Investor Relations
[email protected]
MEDIA CONTACT:
Kristin Gibbs
Chief Marketing Officer
[email protected]
